The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.
 
Ruben Mesa
Consulting or Advisory Role - Constellation Pharmaceuticals; La Jolla Pharma; Novartis; Sierra Oncology
Research Funding - Abbvie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Genentech (Inst); Incyte (Inst); Mays Cancer Center (Inst); NCI (Inst); Promedior (Inst); Samus (Inst)
 
Harinder Gill
Honoraria - Astellas Pharma; BMS; GlaxoSmithKline; MSD; Novartis; Otsuka; Pharmaessentia
Consulting or Advisory Role - GlaxoSmithKline; PharmaEssentia
Research Funding - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pharmaessentia
Patents, Royalties, Other Intellectual Property - COMPOSITIONS AND METHODS FOR FAST MULTIPLEXED SCREENING AND MONITORING OF NPM1 MUTATIONS (International publication number: WO 2023/011624 Al); The University of Hong Kong currently holds two United States (US) patents (7,521,071 B2 and 8,906,422 B2), one Japanese patent (4786341) and one European patent (EP 1562616 B1) for the use of oral arsenic trioxide in the treatment of leukemias and lympho (Inst)
Travel, Accommodations, Expenses - BMS; Jacobson Pharma Corporation (Hong Kong); MSD; Novartis; Otsuka; Pfizer; Pharmaessentia
 
Zhijian Xiao
No Relationships to Disclose
 
Norio Komatsu
Employment - PharmaEssentia Japan K.K
Leadership - PharmaEssentia Japan K.K
Stock and Other Ownership Interests - PharmaEssentia Japan K.K
Consulting or Advisory Role - Torii Pharmaceutical Co., Ltd
Research Funding - Meiji Seika Pharma Co
Travel, Accommodations, Expenses - PharmaEssentia Japan K.K
 
Albert Qin
Employment - PharmaEssentia
Leadership - PharmaEssentia
Stock and Other Ownership Interests - PharmaEssentia
Research Funding - PharmaEssentia
Travel, Accommodations, Expenses - PharmaEssentia
 
Tsewang Tashi
Consulting or Advisory Role - Blueprint Medicines; Cogent Biosciences; Pharmaessentia
Research Funding - Blueprint Medicines; Cogent Biosciences; Glycomimetics; Italfarmaco; Merck; Pharmaessentia
 
Lei Zhang
No Relationships to Disclose
 
Jie Jin
No Relationships to Disclose
 
Keita Kirito
Honoraria - Abbvie; GlaxoSmithKline; Novartis; Pharmaessentia
 
Kohshi Ohishi
Patents, Royalties, Other Intellectual Property - Letters patent of the United States No. 7,399,633" METHODS FOR IMMOTALIZAING CELLS Ohishi K, Varnum-Finney B, Bernstein ID 2008
 
Shuichi Shirane
Speakers' Bureau - Abbvie; Amgen; Asahi Kasei; Novartis Pharma.; Ono Pharmaceutical
 
Lee-Yung Shih
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; PharmaEssentia
Research Funding - Novartis
 
Sung-Eun Lee
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; PharmaEssentia
Research Funding - PharmaEssentia
 
Winnie Z.Y. Teo
Consulting or Advisory Role - BMS; GlaxoSmithKline
Speakers' Bureau - Novartis; Novartis; Pharmaessentia
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Dawn Maze
Honoraria - Celgene/Bristol-Myers Squibb; Jazz Pharmaceuticals; Novartis
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; GlaxoSmithKline; Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Celgene/Bristol-Myers Squibb; Kronos Bio; Novartis; PharmaEssentia; Takeda
 
Stephen Oh
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Celgene/Bristol-Myers Squibb; Constellation Healthcare Technologies; CTIBioPharma; Disc Medicine; Geron; Incyte; Kartos Therapeutics; PharmaEssentia; Sierra Oncol-ogy
 
Toshiaki Sato
Employment - PharmaEssentia Japan K.K
Leadership - PharmaEssentia Japan K.K
Stock and Other Ownership Interests - PharmaEssentia Japan K.K
Research Funding - PharmaEssentia Japan K.K
 
Weichung (Joe) Shih
Consulting or Advisory Role - PharmaEssentia
Travel, Accommodations, Expenses - PharmaEssentia
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Disc Medicine; Galecto; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Keros Therapeutics; Merck; MorphoSys; MorphoSys; Novartis; Pharmaessentia; Roche/Genentech; SOBI; Sumitomo Pharma Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); Disc Medicine; Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); MorphoSys; Novartis (Inst); Pharmaessentia (Inst); SOBI
 
Lucia Masarova
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Cogent Biosciences; Pharmaessentia
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - MorphoSys
 
SURPASS-ET Study Group
No Relationships to Disclose